Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Tivantinib as second line therapy for high-MET HCC

Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy

Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )

3 or 6 months adjuvant oxaliplatin for colorectal cancer

Dr Tim Iveson - University Hospital Southampton, Salisbury, UK

3 or 6 months adjuvant oxaliplatin for colorectal cancer ( Dr Tim Iveson - University Hospital Southampton, Salisbury, UK )

Pooled analysis of avelumab for metastatic urothelial carcinoma

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pooled analysis of avelumab for metastatic urothelial carcinoma ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers

Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers ( Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA )

Routine genomic testing is feasible, but only a subset of patients benefit

Dr Olivier Trédan - Centre Léon Bérard, Lyon, France

Routine genomic testing is feasible, but only a subset of patients benefit ( Dr Olivier Trédan - Centre Léon Bérard, Lyon, France )

Molecular profiles and the future of adjuvant therapy

Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiles and the future of adjuvant therapy ( Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression...

Prof Nick James - Queen Elizabeth Hospital Birmingham & University of...

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression/deaths ( Prof Nick James - Queen Elizabeth Hospital Birmingham & University of Birmingham, UK )

Editor's Choice for May 2017

Prof Gordon McVie - Editor in Chief, ecancer

Editor's Choice for May 2017 ( Prof Gordon McVie - Editor in Chief, ecancer )

EADO conference highlights

Will Davies - Medical Reporter, ecancer

EADO conference highlights ( Will Davies - Medical Reporter, ecancer )

Theory and application of electrochemotherapy

Dr Alessandro Testori - Istituto Europeo di Oncologia, Milan, Italy

Theory and application of electrochemotherapy ( Dr Alessandro Testori - Istituto Europeo di Oncologia, Milan, Italy )

Intralesional T-VEC and combinations for melanoma

Prof Sanjiv Agarwala - St. Luke's Cancer Center, Easton, USA

Intralesional T-VEC and combinations for melanoma ( Prof Sanjiv Agarwala - St. Luke's Cancer Center, Easton, USA )

Molecular testing for targeted therapies

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Molecular testing for targeted therapies ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )

More from ecancer